InnoSkel Appoints Dr Sophie Amsellem-Bosq as Chief Technical Officer InnoSkel Appoints Dr Sophie Amsellem-Bosq as Chief Technical Officer Nice, France, 14 December 2021 – InnoSkel (the “Company”), a pioneering platform biotechnology company developing transformative...

Innoskel Founder and CEO, Elvire Gouze, PhD Receives EY Entrepreneur Of The Year™ Southeast France 2021 Award Innoskel Founder and CEO, Elvire Gouze, PhD Receives EY Entrepreneur Of The Year™ Southeast France 2021 Award Award recognizes Dr. Gouze’s leadership to transform the treatment paradigm for...

InnoSkel Launches with €20 Million Series A Financing InnoSkel Launches with €20 Million Series A Financing Proceeds to support development and advancement of innovative gene therapies for patients with rare skeletal diseases Founded and led by...

Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders Jeito’s third international investment in H2 2020, with deep and rapidly...